Our last E100 survey of biotech execs offered the bleakest industry outlook we’ve tracked in 10 years at Endpoints News. Now we’re back to see if recent signs of improvements in the fundamentals are pointing to increased confidence in the c-suite or proving a temporary mirage. I’ll moderate a panel discussion that takes a look at the results as we explore the biotech landscape at the end of a disruptive 2025.
Register to watch on demand
No cost to register, subject to confirmation.
By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.
If you are experiencing problems with your registration, please contact our support team.